Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Restructuring Costs (2016 - 2018)

Fortress Biotech has reported Restructuring Costs over the past 3 years, most recently at $1.7 million for Q3 2018.

  • Quarterly results put Restructuring Costs at $1.7 million for Q3 2018, down 52.19% from a year ago — trailing twelve months through Sep 2018 was $7.3 million (down 3.91% YoY), and the annual figure for FY2017 was $8.8 million, up 2696.19%.
  • Restructuring Costs for Q3 2018 was $1.7 million at Fortress Biotech, down from $2.3 million in the prior quarter.
  • Over the last five years, Restructuring Costs for FBIO hit a ceiling of $3.6 million in Q3 2017 and a floor of $315000.0 in Q4 2016.
  • Median Restructuring Costs over the past 3 years was $1.8 million (2018), compared with a mean of $1.9 million.
  • Biggest five-year swings in Restructuring Costs: surged 373.97% in 2017 and later plummeted 52.19% in 2018.
  • Fortress Biotech's Restructuring Costs stood at $315000.0 in 2016, then surged by 373.97% to $1.5 million in 2017, then grew by 15.61% to $1.7 million in 2018.
  • The last three reported values for Restructuring Costs were $1.7 million (Q3 2018), $2.3 million (Q2 2018), and $1.8 million (Q1 2018) per Business Quant data.